Company intelligence / Profile preview

The Orchard

London, United Kingdom

Ownership: Private
Employees: ~166
Development stage: Other

Overview

Orchard Therapeutics has developed the approved therapies Libmeldy (atidarsagene autotemcel) for metachromatic leukodystrophy in Europe, UK, Switzerland, and the US, and Strimvelis for adenosine deaminase severe combined immunodeficiency in the EU. The pipeline includes clinical and preclinical-stage gene therapies targeting other rare inherited diseases and neurodegenerative disorders.[2][4][5]

Therapeutic areas: GastroenterologyImmunologyNeurologyRare Diseases
Modalities: Gene therapyEx vivo autologous gene therapyHematopoietic stem cell therapy
Industry: Biotech

Partnerships

San Raffaele Telethon Institute for Gene TherapyThe University of ManchesterGénéthonGlaxoSmithKline (acquired gene therapy portfolio)

Beyond the preview

Go deeper on The Orchard.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on The Orchard.

Explore the full profile